Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India
Annals of African Medicine · 2026
DOI: 10.4103/aam.aam_147_25 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of African Medicine, 2026. Verfasst von Mohammad Arif und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Lung Neoplasms, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Targeted therapy and immunotherapy have improved survival and quality of life in advanced lung cancer. In this study, we evaluated the frequency of programmed death ligand-1 (PDL-1) expression in lung cancer and its association with different clinical and histological subtypes. Materials and Methods: It is a descriptive observational study, in which patients diagnosed with lung cancer were included. PDL-1 testing was done using the monoclonal antibody PDL-1 SP263 primary antibody. The association between the PLD-1 expression with the clinical parameters and histological grading of the disease was analyzed using the Chi-square test.
Results
One hundred and fifty patients were included in our study. The majority of the patients had nonsmall cell lung cancer (90.7%). Among these, 78.7% had adenocarcinoma, 19.1% had squamous cell cancer, and only 2.2% had adeno-squamous cancer. Thirty percent were PDL-1 positive. In patients who were PDL-1 positive, high PDL-1 expression (tumor proportion score ≥50%) was seen in 40%. There was no significant difference seen in PDL-1 expression among different histological subtypes. A significant association of PDL-1 expression was seen with the young age group (34.8% below 60 years vs. 22% above 60 years), and history of tobacco chewing (42% vs. 27%). It was also seen more in men, nonsmokers, in those without history of biomass fuel exposure, less advanced stage, and with no history of pleural invasion. In patients with adenocarcinoma, significantly high PDL-1 expression was seen in those who were negative for EGFR mutation.
Conclusion
Our study has found new and different associations between PDL-1 expression and patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
- Department of Respiratory Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
- Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
- Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Zitieren
APA
Arif, M., Prakash, V., Kumar, H., Shukla, S., Tripathi, A., Singh, M., Kumar, S., & Verma, A. K. (2026). Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India. Annals of African Medicine. https://doi.org/10.4103/aam.aam_147_25
Vancouver
Arif M, Prakash V, Kumar H, Shukla S, Tripathi A, Singh M, et al. Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India. Annals of African Medicine. 2026. doi:10.4103/aam.aam_147_25
BibTeX
@article{Arif2026,
author = {Arif, Mohammad and Prakash, Ved and Kumar, Hemant and Shukla, Saumya and Tripathi, Anurag and Singh, Mrityunjaya and Kumar, Sachin and Verma, Ajay Kumar},
title = {Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India},
journal = {Annals of African Medicine},
year = {2026},
doi = {10.4103/aam.aam_147_25}
}
EUVIMED